There’s also Ostuka’s successor to aripiprazole, brexipiprazole https://en.m.wikipedia.org/wiki/Brexpiprazole
It has different pharmacology and properties, but does have partial agonism at dopamine and serotonin receptors. Here’s an interesting excerpt from Wikipedia, where it describes that brexipiprazole works differently than aripiprazole on dopamine receptors at low doses.
It has different pharmacology and properties, but does have partial agonism at dopamine and serotonin receptors. Here’s an interesting excerpt from Wikipedia, where it describes that brexipiprazole works differently than aripiprazole on dopamine receptors at low doses.
Partial agonists have both blocking properties and stimulating properties at the receptor they bind to. The ratio of blocking activity to stimulating activity determines a portion of its clinical effects. Brexpiprazole has more blocking and less stimulating activity at the dopamine receptors than its predecessor, aripiprazole, which may decrease its risk for agitation and restlessness.[11] Specifically, where aripiprazole has an intrinsic activity or agonist effect at the D2 receptor of 60%+, brexpiprazole has an intrinsic activity at the same receptor of about 45%. For aripiprazole, this means more dopamine receptor activation at lower doses, with blockade being reached at higher doses, whereas brexpiprazole is the opposite. By contrast, brexpiprazole has a much higher affinity for the 5-HT1A receptor than aripiprazole as well as a much higher intrinsic activity. In vivo characterization of brexpiprazole shows that it may act as a near-full agonist of the 5-HT1A receptor.